Wire · opportunities
Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 25 October 2026 · Fusion42 review
The Phase 3 DeLLphi-305 trial shows that tarlatamab plus durvalumab reduces the risk of death by 58% in first-line treatment of extensive-stage small cell lung cancer, extending median overall survival to 21.1 months from 12.7 months for durvalumab alone.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.
◆ ◆ The Wire takeaway
You have a rare new treatment extending survival in first-line small cell lung cancer that also works against brain and liver metastases. Plan now to navigate regulatory routes fast and prepare for the extra post-infusion monitoring your centre will need.
◆ Coverage
1 source · 25 Oct 2026
◆ Related on Wire
◆ Topics